{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:27:33Z","timestamp":1681367253809},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T00:00:00Z","timestamp":1341532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11604-012-0103-6","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T14:50:48Z","timestamp":1341499848000},"page":"642-647","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Makoto","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,6]]},"reference":[{"key":"103_CR1","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804\u201310.","journal-title":"Cancer"},{"key":"103_CR2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424\u201333.","journal-title":"Blood"},{"key":"103_CR3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2005.01.017","volume":"63","author":"AS Gokhale","year":"2005","unstructured":"Gokhale AS, Mayadev J, Pohlman B, Macklis RM. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2005;63:194\u2013201.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"103_CR4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3816\/CLML.2010.n.054","volume":"10","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, et al. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk. 2010;10:258\u201361.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"103_CR5","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:3262\u20139.","journal-title":"J Clin Oncol"},{"key":"103_CR6","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2967\/jnumed.111.089920","volume":"52","author":"K Hohloch","year":"2011","unstructured":"Hohloch K, Delaloye AB, Windemuth-Kieselbach C, G\u00f3mez-Codina J, Linkesch W, Jurczak W, et al. Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network. J Nucl Med. 2011;52:1354\u201360.","journal-title":"J Nucl Med"},{"key":"103_CR7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21:1263\u201370.","journal-title":"J Clin Oncol"},{"key":"103_CR8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"103_CR9","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:2453\u201363.","journal-title":"J Clin Oncol"},{"key":"103_CR10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","volume":"100","author":"K Tobinai","year":"2009","unstructured":"Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;100:158\u201364.","journal-title":"Cancer Sci"},{"key":"103_CR11","doi-asserted-by":"crossref","unstructured":"Emmanouilides C. Radioimmunotherapy for non-Hodgkin lymphoma: historical perspective and current status. J Clin Exp Hematol. 2007;47:43\u201360.","DOI":"10.3960\/jslrt.47.43"},{"key":"103_CR12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cncr.23236","volume":"112","author":"PL Zinzani","year":"2008","unstructured":"Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer. 2008;112:856\u201362.","journal-title":"Cancer"},{"key":"103_CR13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1089\/cbr.2007.359","volume":"22","author":"C Emmanouilides","year":"2007","unstructured":"Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin\u2019s lymphoma. Cancer Biother Radiopharm. 2007;22:684\u201391.","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-012-0103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11604-012-0103-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-012-0103-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T08:15:39Z","timestamp":1594368939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11604-012-0103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,6]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s11604-012-0103-6","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,6]]}}}